Browsing by Author McShane, H

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)
2007Boosting BCG with recombinant modified vaccinia ankara expressing antigen 85A: Different boosting intervals and implications for efficacy trialsPathan, AA; Sander, CR; Fletcher, HA; Poulton, I; Alder, NC; Beveridge, NER; Whelan, KT; Hill, AVS; McShane, H
2009Identification of major factors influencing ELISpot-based monitoring of cellular responses to antigens from mycobacterium tuberculosisSmith, SG; Joosten, SA; Verscheure, V; Pathan, AA; McShane, H; Ottenhoff, THM; Dockrell, HM; Mascart, F
2011A phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adultsMinassian, AM; Rowland, R; Beveridge, NE; Poulton, ID; Satti, I; Harris, S; Poyntz, H; Hamill, M; Griffiths, K; Sander, CR; Ambrozak, DR; Price, DA; Hill, BJ; Casazza, JP; Douek, DC; Koup, RA; Roederer, M; Winston, A; Ross, J; Sherrard, J; Rooney, G; Williams, N; Lawrie, AM; Fletcher, HA; Pathan, AA; McShane, H
2017Predicting IFN-Îł responses after BCG vaccination in humans from macaques: A proof-of-concept study of Immunostimulation/Immunodynamic modelling methodsRhodes, SJ; Sarfas, C; Knight, GM; White, A; Pathan, AA; McShane, H; Evans, TG; Fletcher, H; Sharpe, S; White, RG
2012A review of the tolerability of the candidate TB vaccine, MVA85A compared with BCG and Yellow Fever vaccines, and correlation between MVA85A vaccine reactogenicity and cellular immunogenicityRowland, R; Brittain, N; Poulton, ID; Minassian, AM; Sander, C; Porter, DW; Satti, I; Pathan, AA; Lawrie, AM; McShane, H; Williams, N
2013Roles for Treg expansion and HMGB1 signaling through the TLR1-2-6 axis in determining the magnitude of the antigen-specific immune response to MVA85AMatsumiya, M; Stylianou, E; Griffiths, K; Lang, Z; Meyer, J; Harris, SA; Rowland, R; Minassian, AM; Pathan, AA; Fletcher, H; McShane, H
2009Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in mycobacterium tuberculosis–infected individualsSander, CR; Pathan, AA; Beveridge, NER; Poulton, I; Minassian, A; Alder, N; Van Wijgerden, J; Hill, AVS; Gleeson, FV; Davies, RJO; Pasvol, G; McShane, H
2009Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: Comparison with boosting with a new TB vaccine, MVA85AWhelan, KT; Pathan, AA; Sander, CR; Fletcher, HA; Poulton, I; Alder, NC; Hill, AVS; McShane, H
2014Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.Tanner, R; Kakalacheva, K; Miller, E; Pathan, AA; Chalk, R; Sander, CR; Scriba, T; Tameris, M; Hawkridge, T; Mahomed, H; Hussey, G; Hanekom, W; Checkley, A; McShane, H; Fletcher, HA
2011Th1/Th17 Cell Induction and Corresponding Reduction in ATP Consumption following Vaccination with the Novel Mycobacterium tuberculosis Vaccine MVA85AGriffiths, KL; Pathan, AA; Minassian, AM; Sander, CR; Beveridge, NER; Hill, AVS; Fletcher, HA; McShane, H